Pharmaceutical Technology

OCTOBER 12, 2022

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Under the MoU, the companies will form a collaboration for the development of TRG035, which targets USAG-1 to treat congenital adentia.

Antibody 130

Antibody Development Bioassay Manufacturing 130

Roots Analysis

NOVEMBER 30, 2021

Bioassay – A Prerequisite for the Cell and Gene Therapy Development. In fact, from year 2016 to 2020 more than 300 IND filing for cell and gene therapy product have been recorded, indicating that several developers and innovators are more attracted towards the cell and gene therapies.

Bioassay 52

Bioassay Gene Therapy Gene Development 52

Drug Discovery World

APRIL 25, 2024

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control.

Development 52

Development Bioassay Antibody Drug Delivery 52

Drug Discovery World

APRIL 18, 2024

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control.

Development 52

Development Bioassay Antibody Drug Delivery 52

Drug Discovery World

APRIL 10, 2024

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control.

Development 40

Development Bioassay Antibody Drug Delivery 40

Drug Discovery World

APRIL 4, 2024

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control.

Bioassay 52

Bioassay Antibody Drug Delivery Scientist 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52